Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.

Abstract

Here, we evaluate clinical trials on chemotherapy for patients with pancreatic or biliary tract cancer after first-line treatment failure. Clinical trials on conventional and innovative medical treatments for progressive pancreatic and biliary cancer were analyzed. Metronomic chemotherapy, which consists of the administration of continuative low-dose of anticancer drugs, was also considered. A significant extension of overall survival was achieved with second-line, regimens in patients with gemcitabine-refractory pancreatic cancer. Moreover, many Phase II studies, including chemotherapy and target molecules and immunotherapy, have reported promising results, in both pancreatic and biliary cancer. However, data in these patients' setting are very heterogeneous, and only few randomized studies are available.

• Authors: Concetta Elisa Onesti, Adriana Romiti, Michela Roberto, Rosa Falcone, Paolo Marchetti
• Journal: Expert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 15 Issue 10 Pg. 1183-98 ( 2015) ISSN: 1744-8328 [Electronic] England
• PMID: 26325474 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents

Topics

• Animals
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Biliary Tract Neoplasms (pathology, therapy)
• Disease Progression
• Humans
• Immunotherapy (methods)
• Pancreatic Neoplasms (pathology, therapy)
• Survival Rate
• Treatment Failure
• Treatment Outcome